saral
2021-10-26
Like pls thks.
After-Hours Stock Movers: Ocugen,Ebang International,AnaptysBio,Facebook and more
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
3
10
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":856416813,"tweetId":"856416813","gmtCreate":1635207101367,"gmtModify":1635207102131,"author":{"id":3568944508199908,"idStr":"3568944508199908","authorId":3568944508199908,"authorIdStr":"3568944508199908","name":"saral","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":6,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":80,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Like pls thks.</p></body></html>","htmlText":"<html><head></head><body><p>Like pls thks.</p></body></html>","text":"Like pls thks.","highlighted":1,"essential":1,"paper":1,"likeSize":10,"commentSize":3,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/856416813","repostId":2178147539,"repostType":4,"repost":{"id":"2178147539","pubTimestamp":1635205715,"share":"https://www.laohu8.com/m/news/2178147539?lang=&edition=full","pubTime":"2021-10-26 07:48","market":"us","language":"en","title":"After-Hours Stock Movers: Ocugen,Ebang International,AnaptysBio,Facebook and more","url":"https://stock-news.laohu8.com/highlight/detail?id=2178147539","media":"StreetInsider","summary":"After-Hours Stock Movers:\nOcugen (NASDAQ:OCGN) 34% HIGHER;a meeting by an advisory panel of The Worl","content":"<p>After-Hours Stock Movers:</p>\n<p>Ocugen (NASDAQ:OCGN) 34% HIGHER;a meeting by an advisory panel of The World Health Organisation (WHO) on Tuesday to discuss whether to grant an emergency use listing for its partner’s COVID-19 vaccine named Covaxin.</p>\n<p>Ebang International (NASDAQ:OCGN) 27% HIGHER.</p>\n<p>Vertex Energy, Inc. (NASDAQ: VTNR) 7% LOWER; announced its intention to offer, subject to market conditions and other factors, $155 million aggregate principal amount at maturity of its convertible senior notes due 2027 (the \"notes\") in a private offering (the \"offering\") to persons reasonably believed to be qualified institutional buyers and/or to \"accredited investors\" in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act of 1933, as amended (the \"Securities Act\").</p>\n<p>AnaptysBio, Inc. (Nasdaq: ANAB) 12.2% HIGHER; announced the signing of an agreement with Sagard Healthcare Royalty Partners to monetize a portion of AnaptysBios future JEMPERLI royalties and milestones. AnaptysBio intends to utilize the proceeds of the transaction towards funding of its wholly-owned preclinical and clinical-stage antibody programs.</p>\n<p>Geron Corporation (Nasdaq: GERN) 8.2% HIGHER; announced that imetelstat, the Companys first in class telomerase inhibitor, has been granted an Innovation Passport, which is the first prescribed entry point to the Innovative Licensing and Access Pathway (ILAP) launched in the United Kingdom (UK) by the Medicines and Healthcare products Regulatory Agency (MHRA) in January 2021, post-Brexit. The objective of this new licensing and access pathway is to reduce the time to market for innovative medicines. Key benefits of being within ILAP include a 150-day accelerated assessment and rolling review of a Marketing Authorization Application (MAA), as well as opportunities for frequent interactions with the review staff at the MHRA and its partner agencies, including the National Institute for Health and Care Excellence (NICE), to discuss imetelstats development, regulatory plans and reimbursement plans.</p>\n<p><a href=\"https://laohu8.com/S/CLAR\">Clarus Corporation</a> (NASDAQ: CLAR) 5.5% LOWER; intends to offer, subject to market and other conditions, 2,750,000 shares of common stock registered under the Securities Act of 1933, as amended. The Company also expects to grant to the underwriters an option for 30 days to purchase up to an additional 412,500 shares of common stock.</p>\n<p>Universal Health (NYSE: UHS) 3% LOWER; reported Q3 EPS of $2.67, $0.07 worse than the analyst estimate of $2.74. Revenue for the quarter came in at $3.16 billion versus the consensus estimate of $3.1 billion.</p>\n<p><a href=\"https://laohu8.com/S/FB\">Facebook</a> (NASDAQ: FB) 1.5% HIGHER; reported Q3 EPS of $3.22, $0.03 better than the analyst estimate of $3.19. Revenue for the quarter came in at $29.01 billion versus the consensus estimate of $29.58 billion. Facebook sees Q4 revenue of $31.5 to $34 billion vs consensus of $34.89 billion.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Ocugen,Ebang International,AnaptysBio,Facebook and more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Ocugen,Ebang International,AnaptysBio,Facebook and more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-26 07:48 GMT+8 <a href=https://www.streetinsider.com/dr/news.php?id=19102263><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:\nOcugen (NASDAQ:OCGN) 34% HIGHER;a meeting by an advisory panel of The World Health Organisation (WHO) on Tuesday to discuss whether to grant an emergency use listing for its ...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=19102263\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CLAR":"Clarus Corporation","UHS":"Universal Health Services Inc Cl","ANAB":"Anaptysbio Inc","GERN":"杰龙","VTNR":"顶点能源"},"source_url":"https://www.streetinsider.com/dr/news.php?id=19102263","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2178147539","content_text":"After-Hours Stock Movers:\nOcugen (NASDAQ:OCGN) 34% HIGHER;a meeting by an advisory panel of The World Health Organisation (WHO) on Tuesday to discuss whether to grant an emergency use listing for its partner’s COVID-19 vaccine named Covaxin.\nEbang International (NASDAQ:OCGN) 27% HIGHER.\nVertex Energy, Inc. (NASDAQ: VTNR) 7% LOWER; announced its intention to offer, subject to market conditions and other factors, $155 million aggregate principal amount at maturity of its convertible senior notes due 2027 (the \"notes\") in a private offering (the \"offering\") to persons reasonably believed to be qualified institutional buyers and/or to \"accredited investors\" in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act of 1933, as amended (the \"Securities Act\").\nAnaptysBio, Inc. (Nasdaq: ANAB) 12.2% HIGHER; announced the signing of an agreement with Sagard Healthcare Royalty Partners to monetize a portion of AnaptysBios future JEMPERLI royalties and milestones. AnaptysBio intends to utilize the proceeds of the transaction towards funding of its wholly-owned preclinical and clinical-stage antibody programs.\nGeron Corporation (Nasdaq: GERN) 8.2% HIGHER; announced that imetelstat, the Companys first in class telomerase inhibitor, has been granted an Innovation Passport, which is the first prescribed entry point to the Innovative Licensing and Access Pathway (ILAP) launched in the United Kingdom (UK) by the Medicines and Healthcare products Regulatory Agency (MHRA) in January 2021, post-Brexit. The objective of this new licensing and access pathway is to reduce the time to market for innovative medicines. Key benefits of being within ILAP include a 150-day accelerated assessment and rolling review of a Marketing Authorization Application (MAA), as well as opportunities for frequent interactions with the review staff at the MHRA and its partner agencies, including the National Institute for Health and Care Excellence (NICE), to discuss imetelstats development, regulatory plans and reimbursement plans.\nClarus Corporation (NASDAQ: CLAR) 5.5% LOWER; intends to offer, subject to market and other conditions, 2,750,000 shares of common stock registered under the Securities Act of 1933, as amended. The Company also expects to grant to the underwriters an option for 30 days to purchase up to an additional 412,500 shares of common stock.\nUniversal Health (NYSE: UHS) 3% LOWER; reported Q3 EPS of $2.67, $0.07 worse than the analyst estimate of $2.74. Revenue for the quarter came in at $3.16 billion versus the consensus estimate of $3.1 billion.\nFacebook (NASDAQ: FB) 1.5% HIGHER; reported Q3 EPS of $3.22, $0.03 better than the analyst estimate of $3.19. Revenue for the quarter came in at $29.01 billion versus the consensus estimate of $29.58 billion. Facebook sees Q4 revenue of $31.5 to $34 billion vs consensus of $34.89 billion.","news_type":1},"isVote":1,"tweetType":1,"viewCount":246,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":12,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/856416813"}
精彩评论